Macquarie Group’s Revolution Medicines RVMD Stock Holding History

Macquarie Group’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$624K	Hold	3,331	–	–	﹤0.01%	695
2026 Q1	$324K	Buy	+3,331	New	+$336K	﹤0.01%	733
2025 Q3	–	Sell	-44,565	Closed	-$1.64M	–	1686
2025 Q2	$1.64M	Buy	+44,565	New	+$1.71M	﹤0.01%	1279
2022 Q4	–	Sell	-124	Closed	-$7K	–	2058
2022 Q3	$7K	Sell	124 -228	-65%	-$5.01K	﹤0.01%	2414
2022 Q2	$7K	Hold	352	–	–	﹤0.01%	2492
2022 Q1	$9	Hold	352	–	–	﹤0.01%	2529
2021 Q4	$9K	Hold	352	–	–	﹤0.01%	2523
2021 Q3	$10K	Hold	352	–	–	﹤0.01%	2543
2021 Q2	$11K	Hold	352	–	–	﹤0.01%	2462
2021 Q1	$16K	Sell	352 -108	-23%	-$4.84K	﹤0.01%	2328
2020 Q4	$18K	Hold	460	–	–	﹤0.01%	2243
2020 Q3	$16K	Hold	460	–	–	﹤0.01%	2210
2020 Q2	$15K	Buy	+460	New	+$14.5K	﹤0.01%	2238

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Macquarie Group's RVMD Position: Q2 2026 in Review

Macquarie Group held its Revolution Medicines (RVMD) position steady in Q2 2026 at 3,331 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #695.

Macquarie Group first reported a position in RVMD in Q2 2020 and has held it in 13 quarters since. The position peaked at $1.64M in Q2 2025. 689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Macquarie Group held 3,331 shares of Revolution Medicines worth $624K as of Q2 2026.
Macquarie Group left its Revolution Medicines share count unchanged in Q2 2026.
Revolution Medicines made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #695 holding.
Macquarie Group first reported a position in Revolution Medicines in Q2 2020 and has held it in 13 quarters since.
Macquarie Group's Revolution Medicines position peaked at $1.64M in Q2 2025.
689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.